| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/16/2003 | CN1105559C Anticonvulsant derivative useful in treating neuropathic pain |
| 04/15/2003 | US6548671 Quinoxalinyl amide derivatives |
| 04/15/2003 | US6548638 Peptoid and nonpeptoid containing α-keto oxadiazoles as serine protease inhibitors |
| 04/15/2003 | US6548547 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators |
| 04/15/2003 | US6548522 N-substituted 2,2-diphenylacetamide or N-substituted 2-phenyl-2-pyridinylacetamide |
| 04/15/2003 | US6548520 Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| 04/15/2003 | US6548516 (NMDA=N-methyl-D-aspartate); where the heteroaryl is 3H-benzoxazol-2-one, 3H-benzothiazol-2-one, 3H-benzimidazol-2-one or indolin-2-one; excitatory amino acid antagonists for combating neurodegenerative disorders |
| 04/15/2003 | US6548514 Inhibitors of p38 kinase/cytokine suppressive binding protein (CSBP)/reactivating kinase (RK); 1-((pyridyl)aminocarbonyl)-3-((hetero)arylaminocarbonyl)benzene derivatives; treating cytokine related diseases and disorders |
| 04/15/2003 | US6548510 Pharmaceutical composition containing deoxypeganine for the treatment of nicotine dependence |
| 04/15/2003 | US6548507 Use of sodium channel antagonists in the treatment of diseases mediated or exacerbated by neuronal apoptosis, such as multiple sclerosis; administering drugs such as lamotrigine |
| 04/15/2003 | US6548504 Compounds |
| 04/15/2003 | US6548503 Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| 04/15/2003 | US6548502 Preventing disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction such as drug and alcohol and sex in a mammals by administering pyrido(1,2-a) pyrazine derivatives |
| 04/15/2003 | US6548500 Treating a cell adhesion-mediated diseases such as multiple sclerosis, asthma, atherosclerosis, rheumatoid arthritis, meningitis, comprising administering to a warm blooded animal a nitrogen atoms containing bicyclic compound |
| 04/15/2003 | US6548498 Substituted indan derivatives |
| 04/15/2003 | US6548495 Dihydro-benzo [B] [1,4] diazepin-2-one derivatives |
| 04/15/2003 | US6548494 3,4-dihydro-2H-(1,4)diazepino(6,7,1-hi)indol-1-one or 1-thione derivatives where indole C3 could also be N; use treating cancers as well as stroke, head trauma, and neurodegenerative diseases |
| 04/15/2003 | US6548493 Substituted heterocycle fused gamma-carbolines |
| 04/15/2003 | US6548490 Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 04/15/2003 | US6548484 An amidation product of ribosyl or glucosyl saccharide and a dopamine or derivative ( forms a amide through amine and carboxylic group); useful for treating neurological diseases including Parkinson's and related diseases |
| 04/15/2003 | US6548483 Nutritional preparation comprising ribose and medical use thereof |
| 04/15/2003 | US6548475 Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury |
| 04/15/2003 | US6548284 Membrane-bound metalloprotease and soluble secreted form thereof |
| 04/15/2003 | US6548270 An expression vector comprising a recombinant polynucleotide encoding a protein containing specific amino acid sequence; genetic engineering |
| 04/15/2003 | US6548062 Preferred for the treatment of prostate or pancreatic cancer. |
| 04/15/2003 | US6548061 Repair central nervous system damage; kit containing complement fixing antibodies |
| 04/15/2003 | US6548041 Diagnosis, therapy of central nervous system disorders |
| 04/15/2003 | CA2274338C Ziprasidone formulations |
| 04/15/2003 | CA2097715C Indan derivatives |
| 04/15/2003 | CA2070573C Derivatives of amide analogs of certain methano bridged quinolizines |
| 04/15/2003 | CA2052433C Substituted-4-amino-3-pyridinols, a process for their preparation and their use as medicaments |
| 04/15/2003 | CA2036337C Derivatives of 20,21-dinoreburnamenin, their preparation process and the new intermediates thus obtained, their application as drugs and the compositions containing such |
| 04/12/2003 | CA2407214A1 Method of monitoring neuroprotective treatment |
| 04/11/2003 | WO2002030934A1 Substituted 3.4-dihydro-pyrimido[1,2-a]pyrimidines and 3.4-dihydropyrazino[1,2-a]pyrimidines |
| 04/11/2003 | CA2425685A1 Substituted 3.4-dihydro-pyrimido[1,2-a]pyrimidines and 3.4-dihydropyrazino[1,2-a]pyrimidines |
| 04/10/2003 | WO2003029828A2 Screening method for different indications using bnpi and/or dnpi |
| 04/10/2003 | WO2003029495A2 Coniosulphides and their derivatives, method for their production and use as medicaments |
| 04/10/2003 | WO2003029467A1 Candidate protein for novel cell polarization factor and polynucleotide encoding the protein |
| 04/10/2003 | WO2003029437A2 Secreted proteins |
| 04/10/2003 | WO2003029433A2 Chimeric viral vectors for gene therapy |
| 04/10/2003 | WO2003029424A2 Novel proteins and nucleic acids encoding same |
| 04/10/2003 | WO2003029423A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 04/10/2003 | WO2003029420A2 Apo-2 ligand variants and uses thereof |
| 04/10/2003 | WO2003029410A2 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 04/10/2003 | WO2003029293A2 Modulators of notch ic protease activity for use in immunotherapy |
| 04/10/2003 | WO2003029276A2 Copolymers for suppression of autoimmune diseases, and methods of use |
| 04/10/2003 | WO2003029272A2 A method of treating schizophrenia and bipolar disorders |
| 04/10/2003 | WO2003029252A1 Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| 04/10/2003 | WO2003029250A1 Benzisothiazolyl-substituted aminomethyl chromanes for treating diseases of the central nervous system |
| 04/10/2003 | WO2003029247A1 N-heterocyclyl hydrazides as neurotrophic agents |
| 04/10/2003 | WO2003029245A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 04/10/2003 | WO2003029242A1 NF-λB INHIBITORS |
| 04/10/2003 | WO2003029239A1 Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands |
| 04/10/2003 | WO2003029238A1 Chroman derivatives as 5-hydroxytryptamine-6 ligands |
| 04/10/2003 | WO2003029236A1 Process for the preparation of citalopram |
| 04/10/2003 | WO2003029233A1 New sulfonamide derivatives as d3-receptor agonists |
| 04/10/2003 | WO2003029232A1 Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
| 04/10/2003 | WO2003029221A1 Tetrahydroisochinolines, their production and the use thereof as analgesics |
| 04/10/2003 | WO2003029215A1 4[piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders |
| 04/10/2003 | WO2003029212A1 Indole derivatives as cox ii inhibitors |
| 04/10/2003 | WO2003029210A2 Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| 04/10/2003 | WO2003029200A2 Compounds useful as reversible inhibitors of cysteine proteases |
| 04/10/2003 | WO2003029199A1 Benzene derivatives, process for preparing the same and use thereof |
| 04/10/2003 | WO2003029185A1 Novel compounds |
| 04/10/2003 | WO2003029169A2 Hydroxypropylamines |
| 04/10/2003 | WO2003028768A1 Remedies |
| 04/10/2003 | WO2003028745A1 A composition for lowering the concentration of intestinal pathogenic peptides |
| 04/10/2003 | WO2003028742A1 Strontium compound for treatment of sub-dermal soft tissue pain |
| 04/10/2003 | WO2003028734A1 Triazepine derivatives as neurotrophic agents |
| 04/10/2003 | WO2003028733A1 Tetracyclic indole derivatives as 5-ht receptor ligands |
| 04/10/2003 | WO2003028732A1 Receptor antagonist |
| 04/10/2003 | WO2003028727A1 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors |
| 04/10/2003 | WO2003028723A1 Pharmaceutical compositions for percutaneous absorption containing fused imidazopyridine derivatives |
| 04/10/2003 | WO2003028720A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 04/10/2003 | WO2003028709A2 Use of mannosamine derivatives for the stimulation of neurite growth |
| 04/10/2003 | WO2003028705A1 Pharmaceutical compositions comprising colloidal silicon dioxide |
| 04/10/2003 | WO2003028668A2 Gammaglobulin treatment of immune disorders |
| 04/10/2003 | WO2003028662A2 A method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same |
| 04/10/2003 | WO2003028650A2 Benzimidazolidinone derivatives as muscarinic agents |
| 04/10/2003 | WO2003028641A2 Mch receptor antagonists |
| 04/10/2003 | WO2003028543A2 Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease |
| 04/10/2003 | WO2003028527A2 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 04/10/2003 | WO2003014326A3 Isolation and mobilization of stem cells expressing vegfr-1 |
| 04/10/2003 | WO2003013563A3 Mineral-protein preparations (mpp) and neuropathies in diabetes |
| 04/10/2003 | WO2003011300B1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| 04/10/2003 | WO2003004527A3 Novel neurotrophic factors |
| 04/10/2003 | WO2003004493A8 Novel compounds, their preparation and use |
| 04/10/2003 | WO2003002598A3 Peptides for use as translocation factors |
| 04/10/2003 | WO2003002103A3 Hydrophobic dopamine agonists administered to the dermis |
| 04/10/2003 | WO2003002092A3 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 04/10/2003 | WO2003000709A9 Sialic acid derivatives for use as siglec inhibitors |
| 04/10/2003 | WO2002102978A3 Human growth hormone antagonists |
| 04/10/2003 | WO2002102768A3 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways |
| 04/10/2003 | WO2002099087A3 Cell populations for detecting neuronal targets and potential active ingredients |
| 04/10/2003 | WO2002096467A3 Pharmaceutical use for secreted bacterial effector proteins |
| 04/10/2003 | WO2002094203A3 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 04/10/2003 | WO2002094189A3 Compositions and methods for treating or preventing convulsions or seizures |
| 04/10/2003 | WO2002092064A3 Therapeutic method for inducing tolerance |
| 04/10/2003 | WO2002089738A3 Proteomimetic compounds and methods |
| 04/10/2003 | WO2002083103A3 Pharmaceutical product with reticulated crystalline microstructure |